Pandemic News Links / Current News Updates

trader32176
Posts: 2723
Joined: Fri Jun 26, 2020 5:22 am

Re: Pandemic News Links / Current News Updates

Post by trader32176 »

They are telling us the plan: A future virus “more deadly” than COVID is coming

https://pandemic.news/2021-05-27-virus- ... oming.html


Remember when Bill and Melinda Gates laughed and sneered that the “next pandemic” will get people’s attention? Well, now the World Health Organization is saying the same thing. Kamala Harris is already gearing up for another one too.


(Article by Mac Slavo republished from SHTFPlan.com)

Bill Gates Warning: “We’ll Have a Deadlier Pandemic”

Kamala Harris To The United Nations: “We Must Prepare For” The Next Pandemic


A virus even more transmissible and fatal than Covid-19 (which is pretty easy considering Covid’s death rate is about equal to that of the common cold) will lead the world into the next pandemic, the director-general Tedros Adhanom Ghebreyesus of the World Health Organization (WHO) has said, noting the “evolutionary certainty” of such an occurrence.

Could that “evolutionary certainty” have anything to do with the mass “vaccination” programs being rolled out worldwide? Just a coincidence? You decide.

More COIVD-19 Vax Deaths: Think They’ll Blame This On COVID-21?

Just what do these rulers have planned for the rest of us? Do they have some sort of a “pandemic” designed to actually do damage this time? And still, it all comes back to the “vaccines.”

But the WHO chief stressed that the world remains “in a fragile situation” and cautioned against any nation assuming it is “out of the woods, no matter its [Covid] vaccination rate.” The efficacy of the world’s current crop of Covid-19 vaccines does not appear to be undermined by emerging variants of the virus, such as the strain first detected in India, Ghebreyesus said. But he did warn variants are “changing constantly” and that any future strains could “render our tools ineffective and drag us back to square one.”

Somehow, it looks like they are “readying” the population to begin to accept a surge of deaths. Whether it’s from black, white, or yellow fungus, the “vaccine” or anything else they have decided, matters little. They appear to be telling us that we will need to actually see the horrifying results of their tyrannical takeover to make sure we remain enslaved and obedient.

Too many of the slaves have figured out COVID was a scam. What’s next is anyone’s guess. Stay alert and prepared. Continue to use critical thinking and ask questions. Discernment and logic will be useful skills in the coming year.
curncman
Posts: 1024
Joined: Fri Jun 26, 2020 8:27 am

Newly approved drug heralded as 'game changer' in the growing national obesity crisis

Post by curncman »

Newly approved drug heralded as 'game changer' in the growing national obesity crisis

https://www.yahoo.com/gma/newly-approve ... 19502.html

ABC News
Newly approved drug heralded as 'game changer' in the growing national obesity crisis
ARIELLE MITROPOULOS
Fri, June 4, 2021, 3:26 PM
A new weight-loss treatment is being heralded by some health experts as "groundbreaking," and a potential "game changer" in the growing epidemic of obesity.

Semaglutide, an injectable drug made by the pharmaceutical company Novo Nordisk, was approved Friday by the Food and Drug Administration, for patients struggling with chronic obesity.

"We don't use those terms lightly," Northwestern University Feinberg School of Medicine professor Dr. Robert F. Kushner, an obesity medicine specialist and trial investigator for the drug, told ABC News. "I've been involved in the field for 40 years. The reason we think that way, it results in amount of weight loss of an average of 15% or more, which we have not seen before."

Currently, 42.4% of all adults in the U.S. suffer from obesity, defined as having a body mass index at or above 30, according to the Centers for Disease Control and Prevention.

“Today’s approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program,” John Sharretts, deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research, said in a statement.

Semaglutide was approved in 2019 by the FDA to treat Type 2 diabetes, sold under the brand name Ozempic, albeit at a lower dose. At the higher dose of 2.4 mg, the drug acts on centers in the brain to reduce appetite, leading to potentially significant weight loss when combined with increased physical activity, and counseling sessions with nutritionists to maintain a reduced-calorie diet.

MORE: With obesity on the rise, the best diet may be tailored to our genes, experts say

The drug targets patients with a BMI over 30, or a BMI over 27 with at least one weight-related comorbidity.

In a recent randomized and controlled phase 3 clinical trial study published in the New England Journal of Medicine, researchers at Chicago's Northwestern University studied the drug's impact on weight loss for nearly 2,000 individuals in 16 countries.

"Semaglutide is a paradigm shift from other obesity medications, because it targets the gut as opposed to the brain," said Dr. Anastassios G. Pittas, chief of Endocrinology, Diabetes and Metabolism at Tufts Medical Center.

For 68 weeks, participants injected themselves weekly with either semaglutide or a placebo. On average, over half of those who received the drug itself lost nearly 15% of their body weight, and over a third achieved a weight loss of at least 20% of their weight.

Current anti-obesity drugs on the market result in a weight loss of about 6% to 12%, according to Kushner.

"If someone weighs 200 pounds, or 250 pounds, losing 50 pounds is life-changing," said Dr. Sriram Machineni, also an investigator in the study, and the director of the Medical Weight Clinic at the University of North Carolina.
curncman
Posts: 1024
Joined: Fri Jun 26, 2020 8:27 am

Do Vaccinated Individuals Shed Spike Proteins?

Post by curncman »

Do Vaccinated Individuals Shed Spike Proteins?

trader32176
Posts: 2723
Joined: Fri Jun 26, 2020 5:22 am

Re: Pandemic News Links / Current News Updates

Post by trader32176 »

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals

5/28/21

https://www.news-medical.net/news/20210 ... duals.aspx


Researchers in the Netherlands have provided evidence that a single dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine is sufficient to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people who have already been infected with the virus.

The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose sparing strategies, particularly single vaccine dosing of individuals with prior SARS-CoV-2 infection,” says the team from the University of Amsterdam, the Public Health Service of Amsterdam and members of the RECoVERED Study Group.

Menno de Jong and colleagues showed that among previously infected individuals, one dose of Pfizer-BioNTech’s BNT162b2 vaccine-induced neutralizing antibody titers exceeded those observed among infection-naïve individuals who had received two doses.

These findings support wide implementation of a single-dose mRNA vaccine strategy after prior SARS-CoV-2 infection,” writes the team.

A pre-print version of the research paper is available on the medRxiv* server, while the article undergoes peer review.

“Making use of immunological memory”


Since the COVID-19 outbreak first began in late December 2019, intense global efforts to rapidly develop and clinically test candidate vaccines against SARS-CoV-2 have led to the emergency use authorization of several vaccines that are now being rolled out in many countries.

However, although mass vaccination represents the most promising approach to combating the pandemic, many regions are hampered by limited supplies and resources.

Making use of immunological memory after prior natural SARS-CoV-2 infection, single dosing represents one such strategy for vaccines requiring two doses for optimal efficacy,” says de Jong and colleagues.

Indeed, some studies involving healthcare workers have shown similar or higher antibody responses to a single vaccine after prior infection, compared with two doses following no prior infection.

However, these studies were small, restricted to relatively young and healthy individuals with mostly mild disease and provided limited information on the possible influence of COVID-19 severity and the duration since infection.

What did the researchers do ?

The researchers examined the titers and breadth of antibody responses to a single dose of Pfizer-BioNTech’s BNT162b2 vaccine in 155 individuals previously infected with SARS-Cov-2 who varied widely by age, the presence of comorbidities, COVID-19 severity and time since infection (which ranged from one to 15 months).

Serum antibody titers were determined at the time of vaccination and one week after vaccination. The antibody responses were compared with those observed among 49 SARS-CoV-2-naive healthcare workers (median age 44 years; range 33 to 53 years) who had received two vaccine doses.

The median age of the previously-infected participants was 55 years (range 33 to 61 years), and 44% had one or more comorbidities. Infections were classified as mild in 33% of cases, moderate in 45%, and severe or critical in 22%.

What did they find?

Anti-SARS-CoV-2 immunoglobulin G (IgG) antibody titers were wide-ranging before vaccination, with higher levels observed in participants with previous severe or critical COVID-19.

One week after vaccination, IgG titers against the viral spike protein and its receptor-binding domain (RBD) increased by a median of 29.4-fold and 27.6-fold, respectively.

The spike protein is the main structure SARS-CoV-2 uses to infect host cells, and its RBD is the primary target of antibodies following natural infection or vaccination.

Levels of neutralizing antibodies also increased 12-fold one week following vaccination, compared with prior to vaccination, and exceeded those observed among the fully vaccinated infection-naïve controls.

A Bayesian multilevel regression model showed that pre-vaccination neutralizing antibody titers had the largest positive mean effect size on post-vaccination titers.

Pre-vaccination neutralization titers were associated with higher neutralization titers following vaccination, independent of COVID-19 severity, the presence of comorbidities and the time interval between infection and vaccination.
The findings support wide implementation of a single-dose strategy after prior infection

The researchers say the study demonstrates that higher levels of neutralizing antibodies are achieved within one week of a single dose of BNT162b2 in previously infected individuals, compared with those observed in fully vaccinated SARS-CoV-2-naive individuals, irrespective of the time since infection.

The findings of this study support wide implementation of a single-dose mRNA vaccine strategy after prior SARS-CoV-2 infection to save vaccines and resources, hence expediting vaccination uptake at community levels worldwide,” concludes de Jong and colleagues.

*Important Notice


medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:

de Jong, et al. Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients. medRxiv, 2021. doi: https://doi.org/10.1101/2021.05.25.21257797, https://www.medrxiv.org/content/10.1101 ... 21257797v1


However, although mass vaccination represents the most promising approach to combating the pandemic, many regions are hampered by limited supplies and resources.

Making use of immunological memory after prior natural SARS-CoV-2 infection, single dosing represents one such strategy for vaccines requiring two doses for optimal efficacy,” says de Jong and colleagues.

Indeed, some studies involving healthcare workers have shown similar or higher antibody responses to a single vaccine after prior infection, compared with two doses following no prior infection.

However, these studies were small, restricted to relatively young and healthy individuals with mostly mild disease and provided limited information on the possible influence of COVID-19 severity and the duration since infection.
What did the researchers do?
trader32176
Posts: 2723
Joined: Fri Jun 26, 2020 5:22 am

Re: Pandemic News Links / Current News Updates

Post by trader32176 »

Study: COVID-19 lockdown has led to improvement in air quality in India

6/1/21


https://www.news-medical.net/news/20210 ... India.aspx


Research by scientists from University of Southampton (UK) and the Central University of Jharkhand (India) and has shown the first COVID-19 lockdown in India led to an improvement in air quality and a reduction in land surface temperature in major urban areas across the country.

The study found that travel and work restrictions imposed early in the pandemic resulted in a significant environmental improvement, due to an abrupt reduction in industrial activities and a major decrease in the use of land and air transport.

The international team used data from a range of Earth Observation sensors, including those from the European Space Agency's Sentinel-5p and NASA's MODIS sensors, to measure changes in surface temperature and atmospheric pollutants and aerosols. They concentrated on six major urban areas: Delhi, Mumbai, Kolkata, Chennai, Bangalore, and Hyderabad - comparing data from the 2020 March to May lockdown with pre-pandemic years.

Their findings, published in the journal Environmental Research, provide a strong evidence base for potential environmental benefits through larger scale policy implementation.

The researchers revealed a significant reduction in Nitrogen Dioxide (NO2), a greenhouse gas emitted from the combustion of fossil fuels, which equated to an average decrease of 12 percent throughout India and 31.5 percent over the six cities. There was a 40 percent reduction over the national capital, New Delhi. In India alone, about 16,000 premature deaths occur annually due to exposure to poor air quality.

The study also found Land Surface Temperature (LST) over major cities in India substantially declined in contrast with the previous five-year average (2015-2019) with day temperatures being up to 1°C cooler and those at night up to 2°C cooler.

" The lockdown provided a natural experiment to understand the coupling between urbanisation and local microclimate. We clearly observed that reduction in atmospheric pollutants (due to reduction in anthropogenic activity during lockdown) resulted in a decrease in local day and night-time temperature. This is an important finding to feed into the planning for sustainable urban development."

- Jadu Dash, Co- Author Professor, University of Southampton

Along with surface temperature, the atmospheric fluxes at the surface and top of the atmosphere also significantly declined over major parts of India. The reduction of greenhouse gas concentration, higher atmospheric water vapour content and meteorological conditions played a complex role in the land and near-surface temperature reduction.

Commenting on the research, Dr Bikash Parida, from Central University of Jharkhand said: "Aerosol optical depth (AOD) and absorption AOD showed a significant reduction which could be connected with the reduction in the emission sources across India during the lockdown. The aerosol type sources, such as organic carbon (OC), black carbon (BC), mineral dust, and sea salt also reduced significantly. Moreover, in central India, increases in AOD were attributed to the supply of dust aerosols transported from the western Thar desert region."

Dr Gareth Roberts from the University of Southampton added: "Satellite instruments play a vital role in acquiring information on the Earth's environment in a timely manner. This study has illustrated the importance of Earth Observation data for monitoring changes in the atmospheric pollutants, which are significant health risk, and in highlighting the impact that anthropogenic activities have on regional air quality."

Source:

University of Southampton

Journal reference:

Parida, B.R., et al. (2021) Improvement in air quality and its impact on land surface temperature in major urban areas across India during the first lockdown of the pandemic. Environmental Research. doi.org/10.1016/j.envres.2021.111280.
curncman
Posts: 1024
Joined: Fri Jun 26, 2020 8:27 am

Raleigh biopharma company hopes to have a new treatment for celiac disease

Post by curncman »

Raleigh biopharma company hopes to have a new treatment for celiac disease

https://www.yahoo.com/news/raleigh-biop ... 00886.html

Raleigh-based biopharmaceutical company 9 Meters Biopharma formed just over a year ago, and while slowed by the pandemic, hopes to make significant progress this year in proving the effectiveness of its treatment for celiac disease.

About 1% of the global population suffers from celiac disease, which causes a damaging immune response to gluten in the small intestine, said 9 Meters CEO John Temperato.

“It’s a very sizable population,” Temperato said in an interview with The News & Observer, and there is currently no cure for it.

But 9 Meters, which focuses on treatments for rare digestive disorders, believes its drug Larazotide could provide relief for people suffering from the disease. Larazotide is currently in Phase 3 trials, and Temperato said it’s one of the most advanced clinical trials for a celiac disease treatments. The treatment is only being tested on individuals who are maintaining a gluten-free diet.

Zachery Eanes
Fri, June 4, 2021, 6:00 AM
Raleigh-based biopharmaceutical company 9 Meters Biopharma formed just over a year ago, and while slowed by the pandemic, hopes to make significant progress this year in proving the effectiveness of its treatment for celiac disease.

About 1% of the global population suffers from celiac disease, which causes a damaging immune response to gluten in the small intestine, said 9 Meters CEO John Temperato.

“It’s a very sizable population,” Temperato said in an interview with The News & Observer, and there is currently no cure for it.

But 9 Meters, which focuses on treatments for rare digestive disorders, believes its drug Larazotide could provide relief for people suffering from the disease. Larazotide is currently in Phase 3 trials, and Temperato said it’s one of the most advanced clinical trials for a celiac disease treatments. The treatment is only being tested on individuals who are maintaining a gluten-free diet.

- ADVERTISEMENT -

Those with the disease must follow a strict diet that avoids foods with gluten, a protein found in staple ingredients like wheat and barley. The disease causes gluten to damage the lining of the small intestine, leading to symptoms like diarrhea, fatigue, abdominal pain and nausea.

“It’s a debilitating disease,” Temperato said that can disrupt someone’s day-to-day life. “Unlike high blood pressure or high cholesterol, you know, if somebody is not adhering to (those medical issues), they don’t feel daily issues.”

With celiac disease, it can be a daily nuisance — and maintaining a perfectly gluten-free diet can be expensive. Accidental cross contamination is also common.

“Thirty to 40 percent of patients who are on a gluten-free diet still have celiac symptoms,” Temperato said. “Probably the biggest issue is inadvertent exposure, whether it’s toothpaste or lip balm. (Gluten) is in everything.”

The oral treatment, taken before meals three times a day, attempts to prevent the inflammatory response that gluten causes in the intestines of people with celiac disease.

“You would take our drug with each meal — breakfast, lunch, and dinner — with the goal of (stopping inflammation), while you’re eating and digesting for a couple hours,” he said.

Status of clinical trial
The company should have been closer to completing its clinical trial by this point.

The trial, like many clinical trials in the past year, has been hampered by the COVID-19 pandemic. At one point, more than two-thirds of all trials were being delayed because of struggles to recruit individuals into programs, Fierce Biotech reported.

“We were absolutely impacted by COVID,” Temperato said. “The last thing that patients really wanted to do, when the world was locked down, was to go volunteer in a clinical study.”

At the moment, that means the trial likely won’t be completed until the last few months of this year. Data from the trial, which the U.S. Food and Drug Administration will use to determine its effectiveness, would most likely be available sometime next year, Temperato said.

Image
If the data readout is good, the company hopes to seek approval for its drug in 2023, Temperato added.

Larazotide previously received fast-track designation from the FDA, N.C. Biotech reported. The designation expedites the FDA’s review process for drugs that treat serious conditions or unmet medical needs.

Company profile
9 Meters formed last year after Raleigh-based Innovate Biopharmaceuticals merged with the Israeli firm RDD Pharma and California’s Naia Rare Diseases. (The company’s name is a reference to the approximate length of an adult’s gastrointestinal tract.)

Temperato was the CEO of RDD Pharma before the merger, and prior to that had been an executive at Salix Pharmaceuticals.

In addition to its celiac disease treatment, the company is also developing a treatment for short bowel syndrome.

The company’s stock, which trades on the Nasdaq stock exchange, was up more than 115% over the past year, going from 58 cents a share on June 1, 2020 to $1.25 cents per share at Wednesday’s closing bell.

In April, 9 Meters raised $31 million by selling some of its stock, The Triangle Business Journal reported. According to its most recent quarterly earnings, the company has around $38.5 million in cash on hand.

While based in Raleigh, the company keeps just a small presence here at an office at 8480 Honeycutt Road, with around 10 employees, including Temperato. It also maintains offices in New York, California and Tel Aviv, Israel.

If it wins approval for any of its pipeline drugs, Temperato said the company would invest heavily in boosting its sales and marketing staff.
curncman
Posts: 1024
Joined: Fri Jun 26, 2020 8:27 am

T Ms. Maram - Bone marrow transplantation -BMT

Post by curncman »

T Ms. Maram - Bone marrow transplantation -BMT

curncman
Posts: 1024
Joined: Fri Jun 26, 2020 8:27 am

How to Boost Immune System Naturally | 9 Tips to Strengthen Your Immunity.

Post by curncman »

How to Boost Immune System Naturally | 9 Tips to Strengthen Your Immunity.


curncman
Posts: 1024
Joined: Fri Jun 26, 2020 8:27 am

Aducanumab is a monoclonal antibody that targets part of beta-amyloid, an abnormal protein that accumulates in the brain

Post by curncman »

Aducanumab is a monoclonal antibody that targets part of beta-amyloid, an abnormal protein that accumulates in the brains of Alzheimer’s patients.

https://www.yahoo.com/news/fda-approves ... 31786.html
curncman
Posts: 1024
Joined: Fri Jun 26, 2020 8:27 am

How a distinct type of tau protein could offer a new target for treating Alzheimer's disease

Post by curncman »

How a distinct type of tau protein could offer a new target for treating Alzheimer's disease


https://www.fiercebiotech.com/research/ ... -treatment

Image
Post Reply